Symtomax CBD and Mental Health

Symtomax are aware that mental health is a growing problem. Indeed, a study 2018 study conducted by the Institute for Health Metrics and Evaluation revealed that one in ten people globally have a mental health disorder. Perhaps unsurprisingly, anxiety and depression remain prominent issues for many, with 284 million and 264 million (respectively) suffering from these conditions.

Of course, treatment for mental health issues is never a case of one size fits all. For some, therapy might be the most suitable option, whilst for others medication might provide part of the solution. However, a growing body of research does suggest that perhaps CBD could help to alleviate symptoms, particularly when it comes to anxiety, depression and stress. For more information, please visit Symtomax News.

What is CBD?

Cannabidiol, better known as CBD, is a unique compound derived from the cannabis plant. The plant itself produces over 140  naturally occurring compounds called cannabinoids, which can be extracted for various uses. Find out about all the other cannabinoids in the cannabis plant by visiting Symtomax News.

Whilst many people assume all compounds extracted from the cannabis plant can cause the “high” sensation associated with cannabis, this quality can be largely attributed to the cannabinoid delta-9-tetrahydrocannabinol (THC). CBD, on the other hand is non-psychoactive. It’s very easy to confuse the cannabinoid fact from the fiction, so visit Symtomax News for more information.

Does it work?

Even without psychoactive qualities, however, research suggests that it can still be used to treat certain mental health related issues. Indeed, a 2014 investigation suggested that CBD can have a positive interaction with serotonin receptors in the brain. This means that CBD can aid the balance of serotonin in the brain, which can enhance an individual’s emotional state and feeling of well-being.

In a more recent review in 2018, it was concluded that CBD possesses anti-stress qualities, which could make it a viable treatment for stress and stress-related depression.

In a recent poll, it was revealed that 14% of Americans use CBD products, with 37% of users taking CBD products to treat anxiety, highlighting consumer endorsement of their positive effects on mental health.

What’s next for CBD and Mental Health?

Naturally, it must be remembered that mental health is a complex issue, and so it would be wrong to assume that CBD will automatically resolve mental health issues.

However, it does appear that more consumers are turning to CBD products such as supplements, oils or sprays in a bid to relieve symptoms, proving there is a clear case for its value as an additional relief aid. This is why medicinal cannabis companies including Symtomax are striving to improve consumer experiences of CBD by innovating consumption methods, such as the invention of the Symtomax Oral Tab, which enables the CBD to be administered through the inner lining of the mouth to improve the flexibility of time release, but also increases the amount of medicine available to enter the blood stream. For more information, check out our Symtomax Oral Tabs page. So, with the growing consumer demand and the cannabis industry striving to deliver innovative new products, symtomax group believe that it is likely that the medical industry will see the body of research for this field growing over the coming years.





Read More


Discover how the Porto based medical cannabis company, Symtomax, is poised to conquer the European market and beyond.

Symtomax based in Porto, Portugal are licenced to cultivate, import and export medical cannabis SativaL, with their facility that includes indoor, outdoor and greenhouse cultivation, research and quality control labs as well as processing, packaging and distribution for medical cannabis and cannabinoid-containing products, totalling 105 hectares with 95 hectares approved for cultivation is Europe’s largest outdoor medical cannabis cultivation facility, capable of producing more than 700,000 kilograms per year.



Zimbabwe has planted its first legal hemp crop after it took steps in 2018 to decriminalise cannabis by adopting legalisation policies to tap into the opportunities that exist in this multi-billion dollar industry.

The Zimbabwe Industrial Hemp Trust (ZIHT) and British firm Eco Equity have planted the crops after winning approval from Government to undertake industrial hemp production.

The two firms were allowed to grow the hemp crop after paying a licence of around US$46 000 each.

ZIHT with its funding partner NSK Holdings and technical partner Symtomax  a Portuguese firm planted six varieties of industrial cannabis on a 10-hectare piece of land owned by the Harare Central Prison on the eastern outskirts of the capital.

The planting of the first cannabis crop was witnessed by Lands, Agriculture, Water, Climate and Rural Resettlement Minister Perrance Shiri.

“This project is the first of its kind in the history of our country,” he was quoted saying.

“This pilot project will provide essential knowledge or information for the successful production of this crop. The benefits that will be derived from the production of industrial hemp are enormous and varied.”

In Marondera, about 72km east of Harare, a British firm Eco Equity has also started work on a US$6,3 million medicinal cannabis project.

The company is targeting to complete a greenhouse by April next year and start to plant its first cannabis crop there after.

It expects to begin exports of the product in the third quarter of 2020.

Eco Equity was constructing its greenhouse in partnership with Dutch firm DutchGreenhouses and Australian cannabis company Delta Tetra.

The company secured a long-term lease on a 2 000-hectare piece of land.

“After months of planning, we have moved on to the next exciting phase of our project and we are already seeing the first pictures of the work undertaken,” Jon-Paul Doran, Eco Equity CEO was quoted in the media saying.

“We believe we have the perfect site in terms of both location and climate to cultivate the optimum quality cannabis, which we can use for medicinal purposes. We have employed experts from around the globe to ensure our facilities are cutting edge as we look to provide an alternative natural cure.”

Cannabis plants need four to five months to mature before it is processed into various products.

A well-regulated medical cannabis or industrial hemp industry in Africa has potential to stimulate economic growth and create jobs across the entire continent, a new report reveals.

According to the latest New Frontier Data report titled: “The Africa Regional Hemp and Cannabis Report: 2019 Industry Outlook,” the continent could create over 320 000 jobs in states with legal, regulated markets.

African countries are steadily moving to fast track the approval of regulatory mechanisms to tap into an industry estimated at US$344,4 billion as at 2018.

Although cannabis is still illegal in most African countries, it has been grown on the continent since time immemorial.

Lesotho was the first African nation to legalise medical cannabis in 2017, followed by South Africa’s functional legalisation of adult use in 2018.

In April 2018, Zimbabwe became the second African country to legalise medical cannabis.

New Frontier Data estimates that Africa’s overall market accounts for 11 percent of the total global cannabis market, with US$37,3 billion in combined legal and illegal sales out of the total US$344,4 billion worldwide.

International demand also offers a strong opportunity to unlock the potential value of Africa’s legally produced cannabis, which other researchers estimate could be worth up to US$7,1 billion annually by 2023.

“The hemp industry is a boon to economical equity and balance. It is not wise to take such a valuable resource for granted any longer,” says Dr Zorodzai Maroveke, founder and head of the Zimbabwe Industrial Hemp Trust.

“Africa’s most sizeable cannabis markets are those with the largest populations: Nigeria ($15,3 billion), and Ethiopia ($9,8 billion), followed by Morocco ($3,5 billion), a noted source of hash for most of Europe,” the latest New Frontier Data report on cannabis says.

“The continent’s growth presents opportunities for both medical cannabis and industrial hemp. The plant and the industries surrounding it can support several of the UN’s Sustainable Development Goals (SDGs), including those that are highest priority for African citizens, and some of the low-tech, low-cost, accessible applications of industrial hemp can be quickly activated to support the health and growth of Africa in the coming decades.”

Industrial hemp has a variety of uses that includes ropes, textiles, clothing, shoes, food, paper, bioplastics, insulation, biofuels and hemp jewellery.